Related Experiment Video
Updated: Feb 25, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Changes in Oral Anticoagulant Prescribing for Stroke Prevention in Patients With Atrial Fibrillation
Endalkachew Admassie1, Leanne Chalmers2, Luke R Bereznicki1
1Division of Pharmacy, School of Medicine, University of Tasmania, Tasmania, Australia.
Abstract:
Suboptimal guideline adherence and underuse of anticoagulants in patients with atrial fibrillation (AF) have been reported worldwide. This study aimed to compare anticoagulation practice in Australia during the pre- and postdirect oral anticoagulant (DOAC) eras. Between January 2011 and July 2015, patients with nonvalvular AF (NVAF) admitted to the Royal Hobart Hospital, Tasmania, Australia, were retrospectively reviewed. The pre- and post-DOAC era cohorts included admissions from January 2011 to July 2013 and August 2013 to July 2015, respectively. Overall, 2,118 patients met our inclusion criteria. The overall rate of anticoagulation increased from 52.5% in the pre-DOAC era to 60.7% in the post-DOAC era (p <0.001). Moreover, prescribing of OACs among high-risk patients improved significantly (63.1% vs 55.2%, p = 0.001). OAC overprescribing in low-risk patients did not change significantly between the 2 cohorts (35.0% vs 42.9% in the pre- and post-DOAC eras, respectively, p = 0.59). In multivariate analysis, DOAC era (odds ratio [OR] 1.40, 95% confidence interval [CI] 1.17 to 1.68 and CHA2DS2-VASc ≥2 (OR 1.95, 95% CI 1.36 to 2.80) were independent predictors of OAC prescribing in both eras and the whole study period. Conversely, aging and previous bleeding were inversely associated with OAC prescribing. In conclusion, there has been a significant increase in OAC prescribing in the post-DOAC era, potentially driven by the widespread availability of DOACs. However, OAC underuse in high-risk patients and overuse in low-risk patients was apparent throughout our study. These findings highlight the need to identify the drivers of anticoagulant underuse and overuse and address them accordingly.
Insights
Anticoagulant use in atrial fibrillation (AF) patients increased post-direct oral anticoagulant (DOAC) introduction. However, suboptimal prescribing, including underuse in high-risk patients and overuse in low-risk patients, persists.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Suboptimal guideline adherence and underuse of anticoagulants in atrial fibrillation (AF) are global issues.
- Direct oral anticoagulants (DOACs) have transformed anticoagulation therapy.
- Understanding practice changes in the DOAC era is crucial for improving patient outcomes.
Purpose of the Study:
- To compare anticoagulation practice in Australia during the pre- and post-DOAC eras for nonvalvular AF (NVAF) patients.
- To assess changes in oral anticoagulant (OAC) prescribing rates and identify predictors.
- To evaluate OAC use in relation to patient risk stratification.
Main Methods:
- Retrospective review of 2,118 NVAF patients admitted to Royal Hobart Hospital, Tasmania, Australia.
- Comparison of two cohorts: pre-DOAC era (Jan 2011-Jul 2013) and post-DOAC era (Aug 2013-Jul 2015).
- Multivariate analysis to identify independent predictors of OAC prescribing.
Main Results:
- Overall anticoagulation rate increased from 52.5% to 60.7% (p<0.001) in the post-DOAC era.
- Prescribing improved in high-risk patients (CHA2DS2-VASc ≥2) but remained suboptimal.
- OAC overuse in low-risk patients did not significantly change (35.0% vs 42.9%).
Conclusions:
- The introduction of DOACs has led to a significant increase in OAC prescribing for NVAF patients.
- Despite improvements, significant underuse in high-risk and overuse in low-risk patients persists.
- Further research is needed to address the drivers of suboptimal anticoagulation prescribing in AF.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Venous Thrombosis IV: Nursing Management

